AIDS Care by Medley, Amy et al.
Maximizing the impact of HIV prevention efforts: Interventions 
for couples
Amy Medleya,*, Rachel Baggaleyb, Pamela Bachanasa, Myron Cohenc, Nathan Shafferb, and 
Ying-Ru Lob
aDivision of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA 
bDepartment of HIV/AIDS, World Health Organization, Geneva, Switzerland cDepartment of 
Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA
Abstract
Despite efforts to increase access to HIV testing and counseling services, population coverage 
remains low. As a result, many people in sub-Saharan Africa do not know their own HIV status or 
the status of their sex partner(s). Recent evidence, however, indicates that as many as half of HIV-
positive individuals in ongoing sexual relationships have an HIV-negative partner and that a 
significant proportion of new HIV infections in generalized epidemics occur within serodiscordant 
couples. Integrating couples HIV testing and counseling (CHTC) into routine clinic- and 
community-based services can significantly increase the number of couples where the status of 
both partners is known. Offering couples a set of evidence-based interventions once their HIV 
status has been determined can significantly reduce HIV incidence within couples and if 
implemented with sufficient scale and coverage, potentially reduce population-level HIV 
incidence as well. This article describes these interventions and their potential benefits.
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Introduction
Thirty years into the global fight to curb the HIV epidemic, important gains have been made. 
HIV incidence has declined in 33 countries, 6.6 million people (47% of those eligible) living 
with HIV (PLHIV) are now receiving treatment, and 15 low-resource countries have been 
able to reach at least 80% of pregnant women living with HIV (WLHIV) with antiretroviral 
drugs to prevent vertical transmission (World Health Organization [WHO], United Nations 
Children’s Fund [UNICEF], & Joint United Nations Programme on HIV/AIDS [UNAIDS], 
2011). Despite these advances, 2.5 million people were newly infected with HIV in 2011, 
highlighting the inadequacy of current prevention efforts (Joint United Nations Programme 
on HIV/AIDS [UNAIDS], 2012).
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Access to HIV testing and counseling (HTC) services continues to increase. In a subset of 
87 countries, 72 million HIV tests were conducted in 2010, up from 64 million in 2009 
(WHO, UNICEF, & UNAIDS, 2011). Multiple service delivery models have led to this 
increase including provider-initiated HTC as part of facility-based care, home-based HTC, 
and mobile services. Despite these efforts, population coverage of HTC remains at 40% 
(WHO, UNICEF, & UNAIDS, 2011). Testing individuals remains the norm in most 
programs and few couples test for HIV together (Desgrées-du-Loû & Orne-Gilemann, 
2008). HIV serostatus disclosure to sex partners remains difficult (WHO, 2004), and 
between 20–50% of PLHIV attending clinical care do not know their partner’s HIV status 
(Deribe, Woldemichael, Wondafrash, Haile, & Amberbir, 2008; Mlambo & Peltzer, 2011; 
Sarna et al., 2008).
Integrating partner and couples HIV testing and counseling (CHTC) into routine clinic-
based services (e.g., antenatal, HIV, tuberculosis, and other outpatient services) and 
community-based services (e.g., home and mobile HTC) can significantly increase the 
number of couples, where the status of both partners is known. Encouraging couples to test 
together and to mutually disclose their HIV status allows couples to make joint, informed 
decisions about HIV prevention and reproductive issues, such as contraception and 
conception (Curran et al., 2012). Studies have consistently shown that couples who test 
together are more likely to adopt HIV prevention strategies than individuals who test alone 
(Allen et al., 2003; Burton, Darbes, & Operario, 2010; Rosenberg et al., 2013). CHTC has 
also been shown to increase uptake of interventions to prevent vertical transmission 
(Farquhar et al., 2004), to improve infant outcomes (Aluisio et al., 2010), and to improve 
uptake of and adherence to HIV treatment services (Stirratt et al., 2006; Ware et al., 2009). 
CHTC services are especially important for identifying HIV serodiscordant couples, where 
one member is HIV-infected and the other is not. In sub-Saharan Africa, as many as half the 
PLHIV are in a serodiscordant relationship with current sexual partners (Chemaitelly, 
Cremin, Shelton, Hallett, & Abu-Raddad, 2012). Providing ongoing services to 
serodiscordant couples can prevent HIV transmission to the negative partner. In addition, 
CHTC is an important gateway for linking all couples to appropriate prevention, care, and 
treatment services based on the couple’s serostatus. Table 1 summarizes these services and 
their associated benefits.
Fear of intimate partner violence (IPV) has often been cited by women as a barrier to HIV 
serostatus disclosure and CHTC (Hardon et al., 2012; Medley, Garcia-Moreno, McGill, & 
Maman, 2004; Rujumba et al., 2012). Most studies, however, have not found an association 
between CHTC and an increased risk of IPV incidence even among HIV serodiscordant 
couples (Emusu et al., 2009; Shuaib et al., 2011; Semrau et al., 2005; Were et al., 2011). 
Women with a prior history of IPV may be at higher risk for experiencing adverse events 
following HIV serostatus disclosure or CHTC, than women without this history (WHO, 
2004, 2006). As a result, CHTC counselors should be trained to screen for IPV during the 
pre-test counseling session and to counsel such women about the risks and benefits of 
CHTC. Women with a history of IPV should be provided with ongoing counseling and 
supported in making decisions regarding the safety and feasibility of involving their partners 
in voluntary testing or disclosure. Women currently in a violent relationship should also be 
referred to IPV support services, where available (WHO, 2004, 2012a).
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Recently released guidelines by the World Health Organization (WHO) describe in detail 
the effectiveness and numerous benefits of CHTC (WHO, 2012a). This article complements 
these guidelines by describing interventions that should be offered to couples, once their 
HIV status has been determined (President’s Emergency Plan for AIDS Relief [PEPFAR], 
2011; WHO, 2008, 2012a). These interventions can substantially reduce the risk of 
transmission to HIV-negative sex partner(s) and children and ensure that HIV-positive 
partners receive the care and treatment they need. In generalized epidemics with large 
numbers of serodiscordant couples, these interventions, if implemented in sufficient scale 
and coverage, have the potential to significantly impact the population level HIV incidence 
(El-Sadr, Coburn, & Blower, 2011). While the number of couples living with HIV in 
concentrated epidemics is smaller (1–9% vs. 16–45% in generalized epidemics), the 
proportion of couples who are HIV discordant in these settings is higher (75% in 
concentrated epidemics vs. 50% in generalized epidemics) (Chemaitelly et al., 2012; Dong, 
2011; Klumthanom, 2011). This highlights the need to ensure that couples in both 
generalized and concentrated epidemics have access to these interventions (PEPFAR, 2011; 
WHO, 2012a).
Antiretroviral treatment (ART) for the HIV-positive partner
The clinical trial, HIV Prevention Trials Network (HPTN) 052, showed that providing ART 
to the HIV-positive member in serodiscordant couples reduced the risk of heterosexual 
transmission by 96% (Cohen et al., 2011). These results support the association between 
reduced viral load and lower HIV transmission risk first identified in observational studies 
(Donnell et al., 2010; Quinn et al., 2000). HPTN 052 also confirmed the long debated 
assumption that ARVs can prevent horizontal HIV transmission, as well as vertical 
transmission (Anglemyer, Rutherford, Baggaley, Egger, & Siegfried, 2011; Cohen et al., 
2011). Evidence in a recent ecological report from South Africa indicates substantial 
reduction in HIV incidence in communities with the greatest ART usage, further supporting 
the prevention benefits of ART (Tanser, Barnighausen, Grapsa, & Newell, 2012). These 
findings highlight the importance of ART as an HIV prevention strategy in addition to its 
importance in reducing the morbidity and mortality associated with HIV infection (Cain et 
al., 2011; Severe et al., 2010; Sterne et al., 2009).
Current WHO HIV treatment guidelines recommend initiation of lifelong ART at CD4 
counts of 350/mm3 or lower, including prioritizing ART for eligible pregnant women 
(WHO, 2010a, 2010b). The newly released CHTC guidelines, the first WHO guideline to 
address treatment as prevention, expand this recommendation to include offering ART at 
CD4 counts above 350/mm3 to persons in serodiscordant relationships in order to reduce 
HIV transmission risk to the uninfected partner (WHO, 2012a).
Adherence counseling and support
The success of ART in achieving sustained reductions in viral load depends upon long-term 
retention in care and medication adherence. Effective behavioral interventions to increase 
patient adherence have been described in a number of studies, and include provider-
delivered education or counseling (Kalichman, Cherry, & Cain, 2005; Levy et al., 2004; 
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Pradier et al., 2003; Tuldrà et al., 2000), couple-based counseling (Remien et al., 2005), 
telephone support (Collier et al., 2005), reminder devices (Andrade et al., 2005), home visits 
(Williams et al., 2006), pillbox organizers (Petersen et al., 2007), and directly observed 
therapy (Altice, Maru, Bruce, Springer, & Friedland, 2007; Lucas et al., 2006). Adherence 
counseling should emphasize the importance of medication adherence, both for maintaining 
proper health and for preventing HIV transmission to uninfected sex partner(s) and 
child(ren) (PEPFAR, 2011). In addition, qualitative studies have identified other barriers to 
ART initiation and medication adherence including fear of stigma, fear of the side effects of 
ARVs, fear of taking medications on an empty stomach, and concerns around the transport 
costs associated with treatment (Duff, Kipp, Wild, Rubaale, & Okech-Ojony, 2010; Kahn et 
al., 2013; Murray et al., 2009). In order to maximize ART adherence, providers should 
routinely assess their patients’ concerns around adherence, and provide appropriate 
counseling and support to address these concerns (Simoni, Amico, Smith, & Nelson, 2010).
HPTN 052 participants maintained nearly perfect adherence (and viral load suppression) 
through frequent study visits and direct measurement of blood plasma viral load. While this 
approach is unlikely to be replicated in program settings, the exceptional adherence 
observed in this study suggests that “altruistic adherence” by an HIV-positive partner 
wanting to protect their uninfected partner from HIV may be an important factor to consider 
when designing adherence counseling messages for serodiscordant couples.
Ensuring that PLHIV remain in HIV clinical care after an HIV diagnosis has proven 
challenging with approximately half of PLHIV dropping out of care before initiating ART 
(Larson et al., 2010; Rosen & Fox, 2011). The effect of initiating ART at higher CD4 counts 
on retention in care is unknown. However, preliminary findings indicate that early ART 
initiation may be associated with improved retention in care (Mossdorf et al., 2011; Franke 
et al., 2011). While the mechanism behind this association is unclear, HIV-positive 
individuals may be more likely to remain in care, if they perceive that ART has both health 
and prevention benefits. Further research on how to retain patients in care is needed.
Ongoing risk reduction counseling including condom distribution
Risk reduction counseling is an effective strategy for reducing HIV risk behavior (Allen et 
al., 2003; Crepaz et al., 2006; Kennedy, Medley, Sweat, & O’Reilly, 2010). HPTN 052 and 
other recent studies of discordant couples (Cohen et al., 2011; Donnell et al., 2010; Dunkle 
et al., 2008) have demonstrated that counseling and condom use can reduce HIV 
transmission risk even before the benefits of ART are realized. The incidence of HIV 
transmission in control groups (where the HIV-positive partner was not receiving ART) was 
reduced to less than 2 events/ 100py (Cohen et al., 2011; Donnell et al., 2010). However, the 
risk of virologically unlinked HIV acquisition from an external relationship remained 
substantial (~20–27% of HIV transmission events) even in randomized controlled trials, 
where participants received intensive risk reduction counseling and condoms at every 
follow-up visit (Cohen et al., 2011; Donnell et al., 2010). The persistent risk of HIV 
acquisition from outside relationships demonstrates the failure of current HIV prevention 
interventions at creating sustained behavior change among some individuals. Developing 
more effective prevention strategies to reduce concurrent sexual risk behaviors and increase 
Medley et al. Page 4













condom use with all types of sex partners (Agha, 2012; Chemaitelly & Abu-Raddad, 2013; 
Reynolds, Luseno, & Speizer, 2013) is urgently needed.
Sexual risk reduction counseling (while clearly imperfect) remains an important intervention 
to equip couples with the knowledge and skills necessary to reduce the risk of HIV 
transmission, both within the couple and to outside partners. Sexual risk reduction should 
include messages on partner reduction, mutual monogamy to a partner of known HIV status, 
and consistent condom use at every sexual encounter; a condom demonstration, if needed; 
and condom distribution (PEPFAR, 2011; WHO, 2008). Alcohol reduction counseling 
should also be routinely offered to couples as alcohol use is associated with HIV risk 
behavior (Fisher, Bang, & Kapiga, 2007; Shuper, Joharchi, Irving, & Rehm, 2009), reduced 
adherence to ARVs (Palepu, Horton, Tibbetts, Meli, & Samet, 2004), and poorer health 
outcomes (Baum et al., 2010; Ghebremichael et al., 2009). All couples should be offered 
risk reduction counseling and condom distribution even if the HIV-positive partner(s) is 
receiving ART (PEPFAR, 2011; WHO, 2012a).
Prevention of mother-to-child HIV transmission (PMTCT)
Ensuring that all HIV-positive pregnant women and their male partners are linked to 
PMTCT interventions can significantly reduce or eliminate new pediatric infections and 
improve the health and care-giving ability of WLHIV and their families. WHO guidelines 
on PMTCT and infant feeding recommend: prioritizing eligible pregnant women for ART 
initiation; starting ART or ARV prophylaxis for those not yet eligible for treatment (i.e., 
CD4 counts >350 cells/mm3) during the 2nd trimester; and extending ARV prophylaxis to 
mothers or infants throughout the breastfeeding period (WHO, 2010c, 2010d). Full 
implementation of these guidelines can reduce the rate of vertical transmission to less than 
5% even in breastfeeding populations (WHO, 2010c). This has led to the global goal of 
eliminating MTCT by 2015, defined as reducing new pediatric infections by 90% and 
reducing MTCT rates to <5% (Joint United Nations Programme on HIV/AIDS [UNAIDS], 
2011). Reaching this goal has proved challenging, however, with only 48% of pregnant 
women receiving the most effective PMTCT regimens (WHO, UNICEF, & UNAIDS, 
2011). A new WHO programmatic update on PMTCT options describes the advantages of 
moving toward either triple ARV prophylaxis, or the newly proposed “Option B + ” of 
initiating all WLHIV on lifelong ART upon diagnosis (WHO, 2012b). An important 
rationale for this updated guidance was the added benefit of preventing HIV transmission in 
serodiscordant couples and partnerships in addition to the reduced rates of vertical 
transmission associated with earlier ART initiation.
Integrating male partner testing and couples HIV testing and counseling (CHTC) into 
antenatal services is an effective strategy for increasing women’s uptake and adherence to 
PMTCT interventions and for improving infant outcomes (Aluisio et al., 2010; Becker, 
Mlay, Schwandt, & Lyamuya, 2010; Farquhar et al., 2004). Simply put, women are more 
able to adhere to PMTCT regimens when their male partners are aware of their HIV status 
and supportive of their attendance in HIV care (Medley et al., 2004). HTC in antenatal 
settings is already at a high level, and programs are now beginning to implement CHTC 
services. While some PMTCT programs have experienced challenges in scaling up male 
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partner testing, uptake of CHTC has been high in programs that have prioritized scale-up of 
CHTC services in a comprehensive manner. In Rwanda, for example, the percent of 
pregnant women testing with their male partner increased from 13% in 2003 to 84% by 2010 
following implementation of a multi-component approach that included community 
education, performance contracts between the President of the Republic and local officials, 
performance-based financing for clinic staff, and weekend CHTC services (Republic of 
Rwanda Ministry of Health, 2011).
Family planning and safer conception/pregnancy counseling
Safer conception and pregnancy counseling should be offered to couples who desire a 
pregnancy, as evidence indicates that both pregnant women (Moodley, Esterhuizen, Pather, 
Chetty, & Ngaleka, 2009) and their male partners are at increased risk for acquiring HIV 
during pregnancy (Mugo et al., 2011). Safer conception counseling should not end with the 
pregnancy itself and should include consideration of the couple’s HIV status. HIV-negative 
pregnant women should understand the increased risk of MTCT associated with acquiring 
HIV during pregnancy (Gay et al., 2010; Pilcher et al., 2001; Tuomala et al., 2003). HIV-
positive women should be assessed for whether they are healthy enough for pregnancy, and 
whether their ART regimens, if applicable, are safe and effective during pregnancy.
For couples who do not desire children, prevention of unintended pregnancy among WLHIV 
is an important, yet under-utilized PMTCT strategy. Many women in sub-Saharan Africa, 
both HIV positive and negative, report an unmet need for contraception (Homsy et al., 
2009). Providing family planning counseling and services for couples can reduce the number 
of unintended pregnancies, and ultimately, the number of pediatric infections (Wilcher & 
Cates, 2009). While some observational studies have found that women using progestin-only 
injectable contraception may be at increased risk of HIV acquisition (Baeten et al., 2007; 
Heffron et al., 2012; Morrison et al., 2010), other studies have not found this association 
(Kiddugavu et al., 2003; Kleinschmidt et al., 2007; Myer, Denny, Wright, & Kuhn, 2007; 
Reid et al., 2010). In contrast, the morbidity and mortality risks associated with unwanted 
pregnancy and child-bearing among women, regardless of their HIV status, are substantial 
and have been clearly demonstrated (Rodriguez, Reeves, & Caughey, 2012). These findings 
emphasize the importance of ensuring that women continue to have reliable access to 
contraception. As a result, the WHO recommends that HIV-negative women at high risk for 
HIV acquisition, including those in serodiscordant couples, be strongly advised to 
consistently use condoms and other HIV preventive measures to reduce their risk of 
acquiring HIV, in addition to using a progestin-only injectable to prevent pregnancy (WHO, 
2012c).
Anti-retroviral treatment for pre-exposure prophylaxis (PrEP)
Pre-exposure prophylaxis (PrEP), ART given to the HIV-negative partner prior to HIV 
exposure, may reduce HIV acquisition risk (Baeten et al., 2012; Celum and Baeten, 2012). 
However, concerns have been raised around the feasibility of PrEP as an HIV prevention 
strategy including poor adherence among some uninfected individuals to drugs (Dimitrov, 
Masse, Holte, & Brown, 2012; Van Damme, et al., 2012), a possible increase in sexual risk 
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behaviors (especially with casual partners) if individuals no longer feel at risk for HIV 
acquisition, and the potential spread of antiretroviral drug resistance due to incomplete 
adherence (Van Damme et al., 2012). PrEP, both using topical and oral agents, remains the 
subject of several ongoing clinical trials that should help clarify the efficacy of the 
intervention and offer more clues about utility (Cohen, Muessig, Smith, Powers, & Kashuba, 
2012). In addition, the WHO has released guidance on the use of PrEP among 
serodiscordant couples and other groups at high risk of acquiring HIV (WHO, 2012d). This 
guidance is meant to encourage countries to undertake demonstration projects to determine 
the safety, effectiveness, and sustainability of daily oral PrEP in non-research settings 
(WHO, 2012d).
Voluntary medical male circumcision (VMMC) for HIV-negative male 
partners in serodiscordant relationships
VMMC has been shown to reduce HIV acquisition risk by 60% (Siegfried, Muller, Deeks, & 
Volmink, 2009), and has been recommended by a number of international organizations as a 
key HIV prevention strategy in generalized epidemics (PEPFAR, 2011; WHO, 2012a). 
Population-based data from South Africa have confirmed lower HIV prevalence and 
incidence (55% and 65% lower, respectively) among circumcised men compared to 
uncircumcised men (Auvert et al., 2011). VMMC is an exceptional HIV prevention method, 
in that it offers lifelong partial protection against female-to-male sexual transmission of HIV 
and other STIs. VMMC also provides an opportunity to reach men and boys with HTC 
services including CHTC. Fourteen countries in sub-Saharan Africa have now been 
prioritized for scaling up of VMMC services due to high HIV prevalence and low 
prevalence of male circumcision (World Health Organization [WHO] & Joint United 
Nations Programme on HIV/AIDS [UNAIDS], 2011). To date, more than two million males 
have received VMMC in these priority countries (PEPFAR, 2012). To help increase 
coverage of VMMC, WHO recommends that all HIV-negative men in serodiscordant or 
concordant negative couples be routinely counseled about and linked to VMMC services 
(WHO, 2012a; World Health Organization [WHO] & Joint United Nations Programme on 
HIV/ AIDS [UNAIDS], 2008).
Screening and treatment for other sexually transmitted infections (STIs), as 
indicated
Assessment and treatment of other STIs is important for both patient care and prevention. 
Some STIs may be more complicated and difficult to treat in PLHIV and STI symptoms are 
often more severe in immune-compromised individuals (WHO, 2003). An STI infection can 
also serve as a marker for unprotected sex. Couples who present with an incident STI should 
be targeted for intensive risk reduction counseling. Both members of the couple should be 
assessed and treated for the STI to prevent further transmission and re-infection between the 
couple members (WHO, 2003).
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Repeat HTC for HIV-negative individuals annually
HIV-negative partners in serodiscordant couples should be offered HTC annually to assess 
whether HIV transmission has been successfully prevented (WHO, 2012a, 2010e). 
Concordant negative couples in high prevalence settings, or who are at high risk for HIV 
infection (i.e., couples with outside partners) should also be offered HIV testing annually. 
Individuals or couples who seroconvert should be linked to appropriate prevention, care, and 
treatment services.
Conclusion
HIV prevention, care and treatment services have traditionally been focused on individuals. 
To maximize the benefits of these services, a paradigm shift away from individually-focused 
services and toward couples-focused services is now critically needed. Expanding partner/
couples HTC services in both facility and community settings can significantly increase the 
number of couples, where the status of both partners is known. Couples can then be linked 
to appropriate prevention, care, and treatment services based on the knowledge of their 
serostatus as described in Table 1.
The HPTN 052 data provide important evidence to inform the ongoing debate of whether to 
initiate ART earlier to maximize the prevention benefits associated with treatment. In 
generalized epidemics with a high frequency of serodiscordant couples in stable 
relationships, prioritization for early ART should be given to PLHIV in serodiscordant 
relationships. In addition to early treatment, other interventions for couples described in this 
commentary should be implemented as part of routine practice and incorporated into 
national guidelines. These include adherence counseling and support, risk reduction 
counseling, and condom distribution, family planning counseling and services, STI 
assessment and treatment, and linkage to other HIV prevention services as appropriate (i.e., 
PMTCT, VMMC, and repeat testing for HIV-negative partners).
Engagement and enrollment of male partners remains a challenge in scaling up couples-
based services as men are less likely than women to test for HIV (Peltzer, Matseke, Mzolo, 
& Majaja, 2009; Venkatesh et al., 2011; Ziraba et al., 2011), to enroll in HIV clinical care 
(Cornell, Myer, Kaplan, Bekker, & Wood, 2009; Parrott et al., 2011), to initiate ART 
(Braitstein et al., 2008; Keiser et al., 2008), and to be retained in HIV clinical care 
(Zachariah et al., 2011). In order to bring interventions targeting couples to scale, efforts to 
increase the number of men who know their HIV status and are linked to and retained in 
HIV services are clearly needed. Reluctance to encourage couples interventions has in part 
been due to fears about IPV. While high levels of IPV are reported in many communities, 
the association with HIV testing and disclosure is unclear (WHO, 2004). Health workers 
should be aware of IPV and should be trained how to screen for, address, and make 
appropriate referrals to community-based IPV support services as needed (WHO, 2004, 
2012a).
In summary, current HIV prevention efforts have largely been unsuccessful at curbing the 
HIV epidemic. Highly effective interventions have now been identified that can significantly 
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reduce HIV incidence within couples, and if implemented in sufficient scale and coverage, 
potentially reduce population-level HIV incidence. For the first time since the onset of the 
global HIV epidemic, we now have the tools to meaningfully impact HIV incidence. The 
time has come to implement and scale up what we know works for HIV prevention 
including the interventions described in this article.
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Table 1
List of interventions and their associated benefits according to couple’s HIV serostatus.
Couple’s HIV
status Possible services/interventions Potential benefits
M + /F + • Efficient “case finding” through partner/ couple testing
• Anti-retroviral treatment provision and adherence 
counseling
• Risk reduction counseling
• PMTCT services
• Family planning services
• STI screening and treatment
➢ Earlier ART initiation
➢ Increased HIV prevention with other 
sexual partners
➢ Increased uptake and adherence to FP, 
PMTCT, ART
➢ Increased psychosocial support
➢ Decreased rate of unplanned pregnancy
➢ Decreased risk of mother-to-child HIV 
transmission
M/F • Risk reduction counseling and condom distribution
• Voluntary medical male circumcision
• STI screening and treatment
• Family planning services
• Repeat HIV-testing for couples at high risk
➢ Decreased risk of acquiring HIV from 
other sexual partners
➢ Decreased rate of unplanned pregnancy
➢ Increased emotional support
M + /F • Efficient “case finding” through partner/couple testing
• Earlier ART (ART for prevention)
• Adherence counseling and support
• Pre-conception counseling with ART/PreP for 
prevention
• Risk reduction counseling and condom distribution
• STI screening and treatment
• Family planning services
• Repeat HIV-testing for HIV-negative member
➢ Decreased transmission within current 
relationship and with other sexual 
partners
➢ Safer conception
➢ Increased psychosocial support
➢ Increased uptake and adherence to FP, 
ART
➢ Decreased rate of unplanned pregnancy
M/F + • Efficient “case finding” through partner/ couple testing
• Earlier ART (ART for prevention)
• Pre-conception counseling with ART/PreP for 
prevention
• Risk reduction counseling and condom distribution
• STI screening and treatment
• PMTCT services
• Family planning services
• Repeat HIV-testing for HIV-negative member
• Voluntary medical male circumcision
➢ Decreased transmission within current 
relationship and with other sexual 
partners
➢ Safer conception
➢ Increased psychosocial support
➢ Increased uptake and adherence to FP, 
ART, PMTCT
➢ Decreased rate of unplanned pregnancy
➢ Decreased risk of mother-to-child HIV 
transmission
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